WCM Investment Management LLC reduced its position in shares of UBS Group AG (NYSE:UBS – Free Report) by 1.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,221,697 shares of the bank’s stock after selling 82,824 shares during the quarter. WCM Investment Management LLC owned approximately 0.16% of UBS Group worth $174,614,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in UBS. Grove Bank & Trust bought a new position in UBS Group in the 1st quarter worth $28,000. Maseco LLP bought a new position in UBS Group in the 2nd quarter worth $28,000. Quarry LP bought a new position in UBS Group in the 1st quarter worth $37,000. Berbice Capital Management LLC raised its holdings in UBS Group by 44.4% in the 1st quarter. Berbice Capital Management LLC now owns 1,300 shares of the bank’s stock worth $40,000 after purchasing an additional 400 shares in the last quarter. Finally, Rakuten Securities Inc. raised its holdings in UBS Group by 45.9% in the 1st quarter. Rakuten Securities Inc. now owns 1,466 shares of the bank’s stock worth $45,000 after purchasing an additional 461 shares in the last quarter.
Wall Street Analyst Weigh In
Several research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of UBS Group in a report on Thursday, August 14th. Bank of America upgraded shares of UBS Group from an “underperform” rating to a “neutral” rating in a report on Tuesday, July 22nd. Wall Street Zen lowered shares of UBS Group from a “hold” rating to a “sell” rating in a research note on Sunday, September 28th. Morgan Stanley reiterated an “underweight” rating on shares of UBS Group in a research note on Monday, October 6th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of UBS Group in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, UBS Group currently has a consensus rating of “Moderate Buy”.
UBS Group Stock Performance
Shares of UBS stock opened at $39.09 on Thursday. UBS Group AG has a one year low of $25.75 and a one year high of $42.56. The company’s 50-day moving average is $40.43 and its 200 day moving average is $35.16. The company has a market capitalization of $125.32 billion, a price-to-earnings ratio of 20.68, a price-to-earnings-growth ratio of 0.65 and a beta of 1.18. The company has a debt-to-equity ratio of 3.77, a quick ratio of 1.05 and a current ratio of 1.05.
UBS Group (NYSE:UBS – Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The bank reported $0.72 EPS for the quarter, beating the consensus estimate of $0.70 by $0.02. UBS Group had a net margin of 9.21% and a return on equity of 7.17%. The company had revenue of $11.55 billion for the quarter, compared to the consensus estimate of $9.77 billion. During the same period in the prior year, the firm posted $0.34 EPS. Sell-side analysts expect that UBS Group AG will post 1.9 EPS for the current fiscal year.
About UBS Group
UBS Group AG provides financial advice and solutions to private, institutional, and corporate clients worldwide. It operates through five divisions: Global Wealth Management, Personal & Corporate Banking, Asset Management, Investment Bank, and Non-core and Legacy. The company offers investment advice, estate and wealth planning, investing, corporate and banking, and investment management, as well as mortgage, securities-based, and structured lending solutions.
Featured Articles
- Five stocks we like better than UBS Group
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- Insider Buying Explained: What Investors Need to Know
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Dividend Capture Strategy: What You Need to Know
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for UBS Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UBS Group and related companies with MarketBeat.com's FREE daily email newsletter.